Gemin X Biotechnologies achieved positive preclinical study results evaluating GX15-070 both as a monotherapy and in combination with the proteasome inhibitor Velcade for the treatment of mantle cell lymphoma (MCL). The data demonstrated that GX15-070 induced apoptosis and exhibited synergistic effects with Velcade. In the preclinical study, GX15-070 as a single agent induced apoptosis in vitro in MCL cells lines and in primary cells from MCL patients, with 9 out of 12 patient samples showi...